Exelixis (EXEL) Tops Q2 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St subdued as markets pause after S&P record high; data, Mideast in focus
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Exelixis Announces Second Quarter 2018 Financial Results and Provides Corporate Update
August 1, 2018 4:05 PM EDT- Total Revenues of $186.1 million, Net Income of $87.5 million, Diluted EPS of $0.28 -
- Cabozantinib Franchise Net Product Revenues of $145.8 million -
- Ipsen Royalty Rate Increased to 22 Percent upon Reaching $150.0 million in Cumulative Net Sales -
- Conference Call and Webcast Today at 5:00 P.M. Eastern Daylight Time -
ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the second quarter of 2018 and provided an update on progress toward fulfilling its... More
